Roquefort Therapeutics plc (LON:ROQ – Get Free Report) insider Stephen Paul West bought 15,730 shares of the stock in a transaction on Wednesday, July 12th. The stock was purchased at an average cost of GBX 6 ($0.08) per share, with a total value of £943.80 ($1,214.20).
Stephen Paul West also recently made the following trade(s):
- On Monday, June 26th, Stephen Paul West purchased 144,117 shares of Roquefort Therapeutics stock. The stock was purchased at an average cost of GBX 7 ($0.09) per share, with a total value of £10,088.19 ($12,978.50).
Roquefort Therapeutics Price Performance
Shares of Roquefort Therapeutics stock opened at GBX 6.13 ($0.08) on Thursday. The company has a market capitalization of £7.91 million, a P/E ratio of -306.25 and a beta of -0.03. The stock has a 50-day simple moving average of GBX 6.72 and a 200-day simple moving average of GBX 6.91.
About Roquefort Therapeutics
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Featured Articles
- Five stocks we like better than Roquefort Therapeutics
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
